Advertisement

Advertisement
Dennis J. Slamon, MD, PhD, on Exploiting Cancer Biology in Developing New Treatment Paradigms

Dennis J. Slamon, MD, PhD, on Exploiting Cancer Biology in Developing New Treatment Paradigms

Pertuzumab/High-Dose Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer and Progressive Brain Metastases

Pertuzumab/High-Dose Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer and Progressive Brain Metastases

In the phase II PATRICIA trial reported in the Journal of Clinical Oncology, Nancy U. Lin, MD, and colleagues found that pertuzumab plus high-dose trastuzumab produced central nervous system objective responses and clinical benefit in 68% of patients with HER2-positive metastatic breast cancer with progressive brain metastases.

Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

Long-term analysis of the Short-HER trial showed that 9 weeks of adjuvant trastuzumab conveyed benefits comparable to a 1-year course in patients with early HER2-positive breast cancer deemed to be at low or intermediate risk for disease recurrence. High-risk patients, however, derived considerably more benefit from the conventional longer course, and the study did not meet the noninferiority threshold of significance, investigators reported at the ESMO Breast Cancer Virtual Congress 2021.

Margetuximab-cmkb: A Novel Agent Overshadowed by an Abundance of Options in HER2-Positive Breast Cancer

"It is incredible to reflect upon the scientific advances in the treatment of HER2-positive breast cancer over the past 23 years. Once considered the worst subtype of breast cancer, HER2-positive disease is now associated with the best long-term outcomes in this age of targeted treatments. With a total of eight U.S. Food and Drug Administration (FDA)-approved HER2-directed therapies for advanced disease, four in just the past ~18 months, clinicians and patients now have a number of tools available from which to choose. Though level 1 evidence clearly dictates the current gold standard in the first- and second-line settings (taxane/trastuzumab/pertuzumab and ado-trastuzumab emtansine, respectively), we now have multiple options available after the second line, with no data to guide optimal sequencing," write Sara A. Hurvitz, MD, FACP, and Shiliang Zhang, MD.

Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer

Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer

Drug-related interstitial lung disease occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan-nxki at the approved dose of 5.4 mg/kg. In addition, the majority of these cases were classified as grade 1 or 2, according to findings presented by Charles A. Powell, MD, and colleagues at the ESMO Breast Cancer Virtual Congress 2021.

Biomarker Analysis of the KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy

Biomarker Analysis of the KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy

In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive, hormone receptor–negative breast cancer did not result in a significant improvement in invasive disease–free survival in the node-positive or intent-to-treat population. An updated biomarker analysis of the trial has now confirmed the lack of benefit with the newer regimen in all subgroups of interest, as reported at the ESMO Breast Cancer Virtual Congress 2021 by Otto Metzger, MD.

Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?

Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?

Recent clinical trials have been encouraging for the neoadjuvant or adjuvant use of immune checkpoint inhibitors in triple-negative breast cancer, but is this approach ready for the clinic? This question was addressed at PER’s Miami Breast Cancer Conference, held virtually this year, by Adam M. Brufsky, MD, PhD, Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Comprehensive Breast Cancer Center.1

Advertisement


Advertisement